Please ensure Javascript is enabled for purposes of website accessibility

What's Causing Adamas Pharmaceuticals to Spike Higher Today

By Todd Campbell - Nov 1, 2017 at 3:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Industry watchers are increasingly optimistic about this upstart's future.

What happened

After a leading hedge fund reported it bought shares last month and in the wake of industry watcher upgrades, shares in Adamas Pharmaceuticals (ADMS) rallied more than 10% higher earlier today.

So what

As fellow Motley Fool Brian Orelli pointed out on October 30, legendary hedge fund guru Steven Cohen recently reported a 5.1% equity stake in Adamas Pharmaceuticals. 

A man talking into a bullhorn while standing in front of a chart showing a rising stock price.

IMAGE SOURCE: GETTY IMAGES.

The news his Point72 fund owned 1,144,000 shares sparked a rally that gained additional momentum thanks to Evercore ISI issuing an outperform rating with a sky-high $85 price target earlier this week. 

Today, investors got additional good news when Kerrisdale Advisors, LLC reported it now owned enough shares to give it a 6.5% ownership position. As of June, Kerrisdale reported equity holdings valued at $114 million. For comparison, Point72's equity portfolio totaled more than $15 billion.

Now what

Hedge funds have to disclose when they accumulate large positions in public companies, but that doesn't mean that they plan on holding those shares for long. It could be that Adamas Pharmaceuticals drops out of these portfolios as quickly as it appeared.

Having said that, Adamas Pharmaceuticals' success or failure over the coming year rests heavily on its recently FDA-approved Parkinson's disease drug, Gocovri. Gocovri won an FDA green light on August 24, and management had said it plans a fourth-quarter launch, followed by a ramp upward in its sales force in 2018.

Gocovri is the first drug approved to treat dyskinesia, or involuntary movements, in Parkinson's disease patients. Dyskinesia occurs in about 90% of patients receiving levodopa-based treatment to increase dopamine levels. In trials, Gocovri successfully reduced dyskinesia and off-time, the period during which Parkinson's symptoms return.

Investors interested in adding Adamas Pharmaceuticals to their portfolio might want to wait until third-quarter financials are reported before buying. During the earnings conference call, management's likely to provide an update on the timeline for Gocovri's launch.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Adamas Pharmaceuticals, Inc. Stock Quote
Adamas Pharmaceuticals, Inc.
ADMS

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.